Populations of cells create local environments that lead to emergent heterogeneity. this is particularly evident with human pluripotent stem cells (hPscs): microenvironmental heterogeneity limits hPsc cell fate control. We developed a high-throughput platform to screen hPscs in configurable microenvironments in which we optimized colony size, cell density and other parameters to achieve rapid and robust cell fate responses to exogenous cues. We used this platform to perform single-cell protein expression profiling, revealing that oct4 and sox2 costaining discriminates pluripotent, neuroectoderm, primitive streak and extraembryonic cell fates. We applied this oct4-sox2 code to analyze dose responses of 27 developmental factors to obtain lineage-specific concentration optima and to quantify cell line-specific endogenous signaling pathway activation and differentiation bias. We demonstrated that short-term responses predict definitive endoderm induction efficiency and can be used to rescue differentiation of cell lines reticent to cardiac induction. this platform will facilitate high-throughput hPsc-based screening and quantification of lineage-induction bias.
Populations of cells create local environments that lead to emergent heterogeneity. this is particularly evident with human pluripotent stem cells (hPscs): microenvironmental heterogeneity limits hPsc cell fate control. We developed a high-throughput platform to screen hPscs in configurable microenvironments in which we optimized colony size, cell density and other parameters to achieve rapid and robust cell fate responses to exogenous cues. We used this platform to perform single-cell protein expression profiling, revealing that oct4 and sox2 costaining discriminates pluripotent, neuroectoderm, primitive streak and extraembryonic cell fates. We applied this oct4-sox2 code to analyze dose responses of 27 developmental factors to obtain lineage-specific concentration optima and to quantify cell line-specific endogenous signaling pathway activation and differentiation bias. We demonstrated that short-term responses predict definitive endoderm induction efficiency and can be used to rescue differentiation of cell lines reticent to cardiac induction. this platform will facilitate high-throughput hPsc-based screening and quantification of lineage-induction bias.
hPSCs offer opportunities for drug development, understanding mechanisms of human cell development and cell-based therapies, but these applications require a predictive understanding of factors that control cell fate. Although much progress has been made, there is still a need for improved reproducibility in cell fate-response assays. For example, fibroblast growth factor (FGF) 1,2 , activin A 3,4 , leukemia inhibitory factor (LIF) 5, 6 and Wnt 7, 8 signaling have all been reported both to maintain pluripotency of hPSCs and to have no effect on pluripotency. The International Stem Cell Initiative recently reported the first multilaboratory comparative study of published defined culture systems for hPSC expansion 9 : only two out of eight tested media reproducibly maintained hPSCs across laboratories and cell lines, a result highlighting the need to identify and control key confounding factors.
Population context can have dramatic consequences on stem cell maintenance, differentiation and reprogramming. hPSCs exist high-throughput fingerprinting of human pluripotent stem cell fate responses and lineage bias Emanuel J P Nazareth 1 in complex microenvironments containing multiple factors that regulate cell fate, including endogenous ligands 10 , extracellular matrix proteins 10 , mechanical forces 11 , cell-cell contact 11 and cell subpopulations 2, 10 . Critically, these factors are spatially heterogeneous 10 , and such heterogeneity introduces substantial variances in cell response. Indeed, reprogramming to pluripotency 12 , differentiation toward neural 13 , pancreatic 14 and cardiac 15 cell types, and the disease phenotype of a familial dilated cardiomyopathyinduced hPSC model 16 all have specific organizational and density-dependent optima.
We have developed a suite of tools to test hPSC responses to exogenous factors and to categorize cell lines on the basis of differentiation bias. The platform consists of a method to pattern cells in 96-well plates, an optimized cell-fate factor screening assay protocol, defined media and substrate, and a single-cell imaging and data analysis pipeline. We optimized colony size, cell density, media composition and substrate to allow robust cell fate responses to exogenous cues to be measured at 48 h. Characterization of single-cell protein expression across diverse induction conditions revealed that Oct4 and Sox2 costaining could discriminate pluripotent, neuroectoderm, primitive-streak and extraembryonic subpopulations, enabling fingerprinting of cell-line response to lineage-induction stimuli. These responses were stable between passages, variable between cell lines and predictive of lineage-induction efficiency, and they could be used to improve differentiation of reticent cell lines. Additionally, we applied this platform to characterize 27 developmental signaling factors selected by the International Stem Cell Initiative across a wide range of doses, revealing new dose-and lineagespecific optima.
results microenvironmental control for hPsc screening
We previously developed an assay in which hPSC distribution (colony size, shape and spacing) can be controlled by microcontact printing (µCP) of substrates onto slides. This work indicated that colony size control could be an important parameter in stem cell screens 10 . To adapt this technique for high-throughput studies, we developed a method of µCP in which substrates are directly printed into 96-well plates in user-defined patterns ( Supplementary Fig. 1 ) in defined serum-free medium (SF) and substrate (a fibronectin-and-gelatin mixture, FnGel) ( Supplementary Fig. 2 ). We dispense single-cell suspensions into the wells, allow the cells to settle and adhere to the patterned substrate for 6 h, wash away nonadherent cells, add test factors to the wells for 42 h and then fix and analyze the plates (Fig. 1a) . Each well contains an array of hPSC colonies, and we use automated microscopy to obtain single-cell data such as x and y coordinates and protein expression levels (Fig. 1b) .
On the basis of our current understanding of the relation between colony size and endogenous signaling 10 , we reasoned that calibration of colony size would allow robust detection of both positive and negative regulators of pluripotency. To test this, we assayed the response of hPSC (H9 line) colonies of different sizes to five control conditions: murine embryonic fibroblastconditioned medium (CM), SF base medium alone, SF with fibroblast growth factor 2 (FGF2) and transforming growth factor-beta (TGF-β) inhibitor SB431542 (FTi), SF with bone morphogenetic protein 4 (BMP4, B) and SF with BMP4 and activin A (BA) (Fig. 1c) . We observed that the frequencies of cells expressing the pluripotency factors Oct4 and Sox2 were colony-size dependent, with cells in SF alone maintaining expression in 1,200-µm-diameter colonies and losing expression dramatically in 150-µm colonies. hPSCs in 200-µm colonies were found to respond, relative to baseline SF conditions, with the greatest dynamic range to positive (CM, ANOVA, P = 1.17 × 10 −5 ) and negative (B, ANOVA, P = 2.74 × 10 −4 ) regulators, which indicated that this colony size was ideal for our test criteria. On the basis of the above results and additional optimization (Supplementary Results and Supplementary Fig. 3-5 ), we determined a final assay configuration, which we term the 96µCP platform, that we used for all subsequent 96-well assays (Supplementary Table 1 ).
oct4 and sox2 expression discriminate early cell fates We next sought to determine whether early lineage specification could be quantified using the 96µCP platform. We chose six previously characterized conditions: SF; CM (maintains pluripotency 17 ); SF with heregulin-β1, activin A and FGF2 (HAF, maintains pluripotency 18 ); B (induces trophectoderm and primitive endoderm [19] [20] [21] ); BA (induces primitive streak 21 ); and FTi (induces neuroectoderm 22, 23 ). For all conditions, we assessed single-cell protein expression of a panel of early developmental lineage markers including pluripotency (Oct4, Sox2, Nanog, Tra-1-60), primitive streak (brachyury, Gata4, Snail), neural (Pax6, Sox1, Sox3), extraembryonic (Sox7, Cdx2, Hand1), endoderm (Cxcr4, Foxa2) and mesoderm markers (brachyury, Gata4) (select images in Fig. 2a) . Several later-stage markers, typically arising more than 6 d post-induction, including Pax6, Sox1, Sox3, Sox7, Cdx2, Hand1 and Cxcr4, showed no difference in expression, indicating that at this early test point (42 h), these markers are not differentially expressed, as expected.
Two-dimensional hierarchical clustering of marker expression levels across the six control conditions (Fig. 2b) confirmed that different induction conditions result in distinct protein expression profiles. Thresholds for positive expression were determined for each protein on the basis of differential expression across conditions (Fig. 2c) . SF and FTi conditions clustered together, indicating that under basal conditions the hPSCs are largely neuroectoderm fated, a finding in line with previous observations 24 . Oct4 − Sox2 + , previously shown to mark committed neural precursors in human 25 and mouse 26 development, was seen exclusively in the neuroectoderm-inducing conditions FTi and SF. Oct4 − Sox2 − cells clustered separately from the other groups, which we interpreted as marking a nonpluripotent, non-neural, non-primitive streak population likely fated toward extraembryonic tissue (trophectoderm and primitive endoderm). Primitive-streak markers also clustered together, and, intriguingly, Oct4 + Sox2 − expression clustered with this group. We observed that, across all control conditions, Oct4 + Sox2 − was exclusively found in the BA condition, which induces primitive streak (Fig. 2d,e) and is associated exclusively with high expression levels of Snail, brachyury and Gata4 (Fig. 2f) .
These data support the use of Oct4 and Sox2 as a binary code to discriminate four major early cell fates in human development: Oct4 + Sox2 + for pluripotency, Oct4 − Sox2 + for early neuroectoderm, Oct4 + Sox2 − for early primitive streak and Oct4 − Sox2 − npg for early extraembryonic committed and other tissues (Fig. 2g) . This classification is congruent with previous reports of Oct4 and Sox2 expression in these lineages 19, [27] [28] [29] .
Analysis of early hPsc cell fate responses
We used the 96µCP platform and the Oct4-Sox2 code to simultaneously characterize early cell fates in response to 27 developmental factors. Responding factors ( Fig. 3a; nonresponding factors in Supplementary Fig. 6 ) were classified as promoting pluripotency, neuroectoderm, primitive streak or extraembryonic/other or as having a bimodal effect (inducing different subpopulations at different concentrations). We have summarized the classification of these factors as well as a recommended concentration for use in chemically defined media in Table 1 31 all promoted pluripotency, as predicted from the literature. In contrast, a previously published 7-d nonpatterned hPSC-based screen of 806 human extracellular factors assaying for pluripotency regulators found that only FGF2 and pigment epithelium-derived factor maintained pluripotency-with TGF-β1, activin A, heregulin-β1, IGF1, noggin and all other factors tested resulting in differentiation 32 -highlighting the potential benefits of microenvironmental optimization. Also in agreement with previous observations, the TGF-β inhibitor SB431542 (ref.
3) and the MEK inhibitor PD0325901 (ref. 33 ) reduced pluripotency and increased the neuroectoderm population fraction, whereas BMP4 suppressed pluripotency and neuroectoderm 19 . Activin A plus 40 ng ml −1 BMP4 resulted in a dose-dependent increase in primitive streak, in contrast to activin A alone, which yielded no primitive streak 34 . LDN-193189 (LDN; ref. 35) , an inhibitor of BMP receptors ALK2/3/6 previously uncharacterized in hPSCs, increased neuroectoderm. To determine an optimal dose to inhibit BMP signaling, we obtained the LDN dose curve in the presence of BMP4 (Fig. 3b) . LDN increased neuroectoderm both with and without BMP4 in a dose-dependent manner up to 10 µM LDN. Interestingly, LDN rescued the pluripotency-suppressing effect of BMP at LDN concentrations up to 2.5 µM; however, at higher concentrations pluripotency decreased. Nostro et al. have shown that during endoderm induction from hPSCs, there is a cell line-specific need to inhibit BMP signaling 36 . We therefore added 2.5 µM LDN during stage 2 of the Nostro et al. protocol and confirmed a significant induction of later-stage endodermal PDX1 + pancreatic progenitor cells (P = 0.0006; Fig. 3c ). These results indicate that findings from our high-throughput assay are congruent with results from traditional assays and can yield predictive signaling insights about later stages of differentiation.
It has previously been reported that DKK1 has little or no effect on hPSC pluripotency 8 . However, these studies were performed on hPSCs cultured on fibroblast feeders, measuring formation of alkaline phosphatase-expressing colonies after npg 26 d. In our assay, DKK1 had a surprising effect of inhibiting pluripotency and enhancing neuroectoderm. We speculate that endogenous supporting factors produced by the feeders mask this effect of DKK1. Indeed, when we tested the response of H9 hPSCs to DKK1 in the presence of additional factors (FGF, activin A or BMP), we found that DKK1 no longer induced neuroectoderm (Fig. 3d) .
Quantification of cell-line differentiation propensities
It has long been understood that hPSCs have varying differentiation propensities 37 . We tested whether the 96µCP platform would allow a rapid evaluation of cell line-specific differentiation tendencies by measuring fate responses to six conditions (SF, CM, B, BA, FTi, and SF with PD0325901) for 21 cell samples. Our test panel consisted of 15 human embryonic stem cell (hESC) and human induced pluripotent stem cell (hiPSC) lines, including two in-house-generated hiPSC lines, ZAN3i-85UCBT (ZAN3) and Fig. 7 and Online Methods); an in-house-generated karyotypically abnormal H7 cells (H7*) with trisomy 12, which is recurrent in hPSC cultures; differentiated H9 cells (H9diff); and multiple passages of H9 and ZAN11. We performed two-dimensional hierarchical clustering on this data set (6 controls × 4 subpopulation measurements = 24 data points for each cell line), which enabled visualization of cellline similarities (Fig. 4a) . The H7* line expressed all pluripotency markers and had normal hPSC morphology but was the only line that failed to differentiate in response to BMP4, which is indicative of an acquired abnormality ( Fig. 4b and Supplementary  Fig. 8 ). The three passages of H9 and ZAN11 cells clustered closely; such clustering indicates that the response profile is stable over multiple passages and that the assay is reproducible. We sought to determine whether our 48-h factor response profiles could be used to improve differentiation protocols for specific cell lines. Despite the overall similar differentiation profile npg of ZAN3 and ZAN11 lines (Fig. 4a) and similar primitive-streak induction frequency in response to BMP and activin A, when activin A was removed, ZAN3 cells increased primitive-streak induction, in contrast to ZAN11 and H9 cells, in which primitivestreak induction decreased. This trend was confirmed over multiple passages (ANOVA, P = 0.005) (Fig. 4c) . To further support the primitive-streak commitment of these lineages and to associate this early cell fate with functional commitment, we compared the cardiac differentiation efficiency of ZAN11 and ZAN3 in an 18-d protocol 38 . We varied activin A concentration during the first 4 d, as differentiation is known to be sensitive to activin A in a cell line-dependent manner during this period 39 . As predicted by the day 2 results (Fig. 4c) , day 18 cardiac troponin T (TnT) expression varied with activin A (P = 0.005, twofactor ANOVA with n = 2, independent passages), with additional activin A increasing cardiomyocyte (TnT + ) output in ZAN11 but decreasing cardiomyocyte output in ZAN3 (both >95% confidence using linear regression; Fig. 4c ).
ZAN11i-85UCBT (ZAN11) (Supplementary
To further examine how predictive the day 2 96µCP response profiles were of differentiation over longer periods, we differentiated a panel of 12 hESC and hiPSC lines toward Foxa2 + Sox17 + definitive endoderm using a 5-d induction protocol (Fig. 4d and  Supplementary Fig. 9a) . Using the ratio of percent primitive streak induced in the BA control to percent extraembryonic in the CM condition ('mesendoderm prediction index'), we found a significant correlation between this day 2 prediction index and cell-line definitive endoderm induction efficiency at day 5 (correlation coefficient r = 0.89, P = 0.0001; Fig. 4d and Supplementary  Fig. 9a,b) . In contrast, pluripotency of the input cell population was not correlated with definitive endoderm induction (r = 0.29, P = 0.42; Supplementary Fig. 9c ).
Quantification of cell-line endogenous signaling
Our results thus far and several recent studies indicate that variability in endogenous signaling is one major source of cell-line differentiation variability. Cell line-and passage-specific changes in endogenous activin A 39 and Wnt 24 signaling are known to dramatically reduce cardiac induction efficiency. We reasoned that, by measuring responses to saturating agonists and antagonists of specific pathways, endogenous signaling levels could be assessed and quantitatively placed along a spectrum of low activation (endogenous response equivalent to pathway inhibitors) to high activation (endogenous response equivalent to saturating agonists).
We determined from dose curves the saturating concentrations of factors that affect early cell fate decisions (Fig. 3a) . Using H9 cells, we then tested the response to agonists and antagonists of the major pathways regulating hPSC fate (Fig. 4e) . To obtain an estimate of activation of an endogenous pathway relative to its dynamic range (percent dynamic range), we combined agonist, antagonist and baseline control measurements (Online Methods equation (1)). The resulting endogenous signaling profile for activin, FGF, EGF, Wnt and BMP activation in H9 is shown in Figure 4e . We used similar quantitative profiles to compare H9 to ZAN11 and ZAN3 lines, revealing that EGF, FGF and activin are all differentially endogenously activated ( Fig. 4f and  Supplementary Fig. 10 ). Comparisons of control and pathway agonist-antagonist response profiles over multiple passages indicate high correlation between passages (ZAN11 r = 0.90 and ZAN3 r = 0.88) and lower correlation between cell lines (ZAN11 vs. ZAN3 r = 0.52) (Fig. 4g) . In summary, cell lines differ in their response to induction conditions and specific pathway agonists and antagonists, and this response is stable between passages. These response-profile measurements offer a quantitative tool for rapidly fingerprinting hPSC signaling profiles. discussion Heterogeneity in cell response in clonal populations arises from many cell-autonomous and non-cell-autonomous factors. Our previous work 10 and other diverse evidence led us to hypothesize that controlling key sources of microenvironment variance and optimizing colony size and density would allow robust cell response and thus overcome existing limitations in hPSC highthroughput assays. In comparison to previous assays, our 96µCP platform eliminates the need to seed in CM, results in less hPSC cell fate response variance and faster response kinetics and, in npg conjunction with Oct4 and Sox2 marker analysis, allowed us to screen for cell fate responses to 27 developmental factors, thereby providing the most comprehensive characterization of hPSC cell fate decisions to date.
Our 48-h high-throughput stem cell response-signature approach is a direct measurement of early transcription factor expression changes in response to diverse exogenous cues. In combination with cell line-specific epigenetic and gene expression data 40 , this may offer a strategy to decipher the genetic and epigenetic basis of cell line-specific responses to cues. Additionally, hiPSC lines can now be generated at a higher rate than they can be characterized. We propose the 96µCP platform as an effective first-pass assay to detect tumorigenic cell lines and quantify neuroectoderm and primitive-streak differentiation propensity. Further development may lead to a simple and effective in vitro teratoma surrogate assay.
Finally, population heterogeneity arising from microenvironmental differences applies broadly to adherent cell populations and is increasingly recognized as a major obfuscating factor in drug-screening campaigns 41 . We believe that the methods presented herein are widely applicable to adherent cell types. We have developed 96µCP based assays for mouse epiblast stem cells and hPSC-derived cardiac and endoderm cells with minimal modification to the base medium, substrate and pattern size. Applying these concepts toward rapid characterization of the signaling involved in cell fate decisions of differentiated cell types is a promising strategy to accelerate the drive toward clinical regenerative medicine and drug screening of hPSC disease models. methods Methods and any associated references are available in the online version of the paper. Activin A has differential effects on cardiac TnT expression in ZAN3 and ZAN11 cell lines (P < 0.005, two-factor ANOVA with n = 2, independent passages), with activin A increasing primitive streak in ZAN11s and decreasing primitive streak in ZAN3s (both >95% confidence using linear regression). 
